Close

Not a member yet? Register now and get started.

lock and key

Sign in to your account.

Account Login

Forgot your password?

Healthcare  // Browsing posts in Healthcare

Depomed Idea Proposal (DEPO)

Depomed Idea Proposal (DEPO)

Research Question: Will Depomed’s Nucynta and Nucynta ER achieve blockbuster status as it takes on OxyContin with acute pain patients and Lyrica/Cymbalta with neuropathic pain patients? Report Available: Oct. 29, 2015   Blueshift’s initial research shows DEPO sold $57 million worth of painkiller Nucynta in its first quarter and believes it has the potential to reach $1 […]

Read more...

Seres’ SER-109 Likely Will Be the First Microbiome Therapy to Market

Research Question: Will Seres Therapeutics’ SER-109 be the first approved and best microbiome therapy to treat Clostridium difficile infections? Companies: ALIOF/VTX:ATLN, MCRB, MRK, NVS, PFE, SHPG, SNY, SYN By: David Franklin Click here to download the report (.pdf)   Summary of Findings Seres Therapeutics Inc.’s (MCRB) Phase 2 drug, SER-109, is expected to be the first […]

Read more...

Scotts Miracle-Gro Idea Proposal (SMG)

Scotts Miracle-Gro Idea Proposal (SMG)

Research Question: Will Scotts Miracle-Gro’s entry into the hydroponics/marijuana market spur the company into high-growth mode?   Report Available: Oct. 23, 2015   Blueshift’s initial research shows SMG expanding into the hydroponics market, a sector likely to experience double-digit growth for years to come. However, hydroponics’ user base, many of whom grow marijuana, shudder at […]

Read more...

Abiomed Idea Proposal

Abiomed Idea Proposal

Research Question: Will the Impella propel Abiomed to achieve its 40% growth projections? Report Available: October 14, 2015   Blueshift’s initial research shows ABMD’s Impella utilization rate is increasing faster than many had expected in its Q1. ABMD, a leader in heart support technologies, then issued an aggressive five-year strategy which predicted $1.2 billion to $1.8 billion in […]

Read more...

Seres Therapeutics Idea Proposal

Seres Therapeutics Idea Proposal

Research Question: Will Seres Therapeutics’ SER-109 be the first approved and best microbiome therapy to cure Clostridium difficile infection? Report Available: October 1, 2015   Blueshift’s initial research shows MCRB’s SER-109 garnering much support from Wall Street and the FDA,which should hasten its time to market. Given SER-109’s exceptional 97% cure rate for the infectious CDI, MCRB hopes […]

Read more...

Exact Sciences’ Cologuard the Preferred Test for Patients Refusing Colonoscopy (EXAS)

Research Question: Will Exact Sciences’ Cologuard become physician’s screening test of choice for colon cancer? Companies: ABT, BDX, BIOC, BSX, CHEK, CPHD, DGX, EXAS, FMI, GIVN, GSK, IRWD, RHHBY By: David Franklin Click here to download the report (.pdf)   Summary of Findings Exact Sciences Corp.’s (EXAS) Cologuard has high clinical value, but it is unlikely […]

Read more...

Exact Sciences Whisper

Exact Sciences Whisper

Research Question: Will Exact Sciences’ Cologuard become the colon cancer screening test of choice for physicians? Report Available: August 14, 2015   Blueshift’s initial research shows EXAS’s Cologuard, a non-invasive test for colon cancer, is monetizing at a significant rate following FDA approval and an increased sales staff. But some physicians argue the screener should not be […]

Read more...

Well-Received Zarxio Will Pave Way to Eventual Wide Biosimilar Adoption

Research Question: Will Sandoz’s (Novartis) Zarxio, the first biosimilar approved by the FDA, be widely adopted by the medical and managed care community and pave the way for future biosimilars? Companies: AMGN, BOM:500359, EPRS, ESRX, HSP, KOSDAQ:068270, NVS, MRK, PFE By: Linda Richards Click here to download the report (.pdf)   Summary of Findings Adoption of […]

Read more...

Biosimilars Whisper

Biosimilars Whisper

Research Question: Will Novartis’ Sandoz Zarxio, the first biosimilar approved by the U.S. FDA, be widely adopted by the medical and managed care community and pave the way for future biosimilar drugs? Companies Covered: Amgen (AMGN), Novartis AG (NVS), Hospera (HSP), Celltrion (068270.KQ), Merck (MRK), Express Scripts (ESRX) Report Available: May 21, 2015   Blueshift’s […]

Read more...

Teva’s Long-Term Success Will Depend on Strategic Acquisitions

Research Question: Will Teva’s growth initiatives be enough to overcome the Copaxone patent cliff and increasing generic drug competition? Companies: ACT, AZN, BIIB, HSP, MYL, NVS, PFE, SLXP, TSE:VRX, TLV:TEVA By: Linda Richards Click here to download the report (.pdf)   Summary of Findings Ten sources who commented offered mixed responses on the likelihood of Teva Pharmaceutical Industries […]

Read more...